Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis.

[1]  Shou-Dong Lee,et al.  Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  P. Ott,et al.  Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis. , 2008, World journal of gastroenterology.

[3]  Angelo Luca,et al.  Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. , 2006, Gastroenterology.

[4]  R. Groszmann,et al.  Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. , 2006, Journal of hepatology.

[5]  J. Bosch,et al.  Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis , 2006, The American Journal of Gastroenterology.

[6]  O. Opitz,et al.  Effect of vardenafil, an inhibitor of phosphodiesterase‐5, on portal haemodynamics in normal and cirrhotic liver – results of a pilot study , 2006, Alimentary pharmacology & therapeutics.

[7]  Ramon Planas,et al.  Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. , 2005, The New England journal of medicine.

[8]  O. B. Schaffalitzky de Muckadell,et al.  Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. , 2005, American journal of physiology. Renal physiology.

[9]  E. Bischoff.  Potency, selectivity, and consequences of nonselectivity of PDE inhibition , 2004, International Journal of Impotence Research.

[10]  R. Groszmann,et al.  The hepatic venous pressure gradient: Anything worth doing should be done right , 2004, Hepatology.

[11]  J. Corbin,et al.  Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. , 2003, Journal of andrology.

[12]  J. Rodés,et al.  Hemodynamic response to pharmacological treatment of portal hypertension and long‐term prognosis of cirrhosis , 2003, Hepatology.

[13]  A. Friebe,et al.  Rapid nitric oxide–induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme , 2001, The Journal of cell biology.

[14]  L. J. Sampson,et al.  Evidence for expression and function of phosphodiesterase type 5 (PDE‐V) in rat resistance arteries , 2001, British journal of pharmacology.

[15]  M. Aldasoro,et al.  Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. , 2000, The Annals of thoracic surgery.

[16]  J. Huidobro-Toro,et al.  Molecular mechanism of cGMP‐mediated smooth muscle relaxation , 2000, Journal of cellular physiology.

[17]  T. Gupta,et al.  Low‐dose midazolam sedation: An option for patients undergoing serial hepatic venous pressure measurements , 1999, Hepatology.

[18]  T. Gupta,et al.  Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats , 1998, Hepatology.

[19]  E. Sybertz,et al.  Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. , 1991, Advances in experimental medicine and biology.